Odyssey Therapeutics
Raise: TBD
Public Market Debut: TBD
Odyssey Therapeutics is giving its IPO aspirations another go, announcing on April 17 another bid to debut on the Nasdaq Capital Market. The biotech is still fairly early into its offering, so it has yet to provide a specific raise target or a definitive timeline for the push.
The company has, however, determined that its IPO proceeds will go toward its lead candidate OD-001, a small-molecule scaffolding blocker of the RIPK2 protein, according to its preliminary prospectus. The money will help move OD-001 through planned Phase 2a and Phase 2b studies in ulcerative colitis.
Odyssey’s IPO will also help push the SLC15A4 program OD-002 through investigational new drug-enabling activities and into Phase 1/2a development. “These programs have the potential to yield treatments for inflammatory and autoimmune diseases that have large, addressable patient populations globally,” the biotech wrote in its securities filing.
Odyssey first tried for an IPO in January 2025, though the biotech’s programs were still preclinical at the time. In June last year, Odyssey decided to end its bid. It did not provide specific reasons for pulling its IPO, only noting in an SEC document that going public “is not in the best interests of the company.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.